Multiple Myeloma (Treatment)

Phase III Results for Tumor Purging Trial Announced

Published in Blood Weekly, June 30th, 1997

The Ceprate SC Stem Cell Concentration System reduced myeloma cells in blood stem cell transplant patients in a clinical trial.

CellPro Inc., Seattle, Washington, announced preliminary results of its Phase III clinical trial using the Ceprate SC Stem Cell Concentration System to select peripheral blood stem cells from patients with multiple myeloma. These results were presented at the VI International Workshop on Multiple Myeloma, held in Boston, Massachusetts, during June 1997.

The open-label, randomized clinical trial was initiated in January 1995 at 15 sites in the United States and Canada and enrolled 134 patients eligible for a peripheral blood...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Blood Weekly

Source: Blood Weekly (1997-06-30)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry